ECSP13013038A - Inhibidores sustituidos de acetil-coa carboxilasa - Google Patents
Inhibidores sustituidos de acetil-coa carboxilasaInfo
- Publication number
- ECSP13013038A ECSP13013038A ECSP13013038A ECSP13013038A EC SP13013038 A ECSP13013038 A EC SP13013038A EC SP13013038 A ECSP13013038 A EC SP13013038A EC SP13013038 A ECSP13013038 A EC SP13013038A
- Authority
- EC
- Ecuador
- Prior art keywords
- coa
- carboxilasa
- acetil
- inhibitors
- replaced
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 abstract 1
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 abstract 1
- 108010018763 Biotin carboxylase Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Enzymes And Modification Thereof (AREA)
- Photographic Processing Devices Using Wet Methods (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
La invención proporciona un compuesto de Fórmula (I)Fórmula (I)o una sal del mismo aceptable desde el punto de vista farmacéutico; donde G esR1, R2 y R3 son como se describe en la presente; composiciones farmacéuticas del mismo; y el uso del mismo en el tratamiento de enfermedades, afecciones o trastornos modulados por la inhibición de una enzima(s) acetil-CoA carboxilasa en un animal.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161478240P | 2011-04-22 | 2011-04-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP13013038A true ECSP13013038A (es) | 2014-01-31 |
Family
ID=46025823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP13013038 ECSP13013038A (es) | 2011-04-22 | 2013-11-22 | Inhibidores sustituidos de acetil-coa carboxilasa |
Country Status (42)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101478517B1 (ko) * | 2009-11-10 | 2015-01-02 | 화이자 인코포레이티드 | Ｎ1-피라졸로스피로케톤 아세틸-ｃｏａ 카복실라아제 억제제 |
| CN102491974B (zh) | 2011-12-12 | 2013-08-07 | 南京药石药物研发有限公司 | 1-（2-氟苄基）-1H-吡唑并[3，4-b]吡啶-3-甲脒盐酸盐的合成方法 |
| EP2970104B1 (en) | 2013-03-14 | 2019-04-24 | Zeno Royalties & Milestones, LLC | Bicyclic analgesic compounds |
| MX2015015416A (es) | 2013-05-10 | 2016-06-21 | Nimbus Apollo Inc | Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos. |
| US10208063B2 (en) | 2013-05-10 | 2019-02-19 | Gilead Apollo, Llc | ACC inhibitors and uses thereof |
| KR20160007598A (ko) | 2013-05-10 | 2016-01-20 | 님버스 아폴로, 인코포레이티드 | Acc 억제제 및 이의 용도 |
| EP3043800A1 (en) | 2013-09-12 | 2016-07-20 | Pfizer Inc. | Use of acetyl-coa carboxylase inhibitors for treating acne vulgaris |
| JPWO2015056782A1 (ja) | 2013-10-17 | 2017-03-09 | 塩野義製薬株式会社 | 新規アルキレン誘導体 |
| EP3080072A4 (en) * | 2013-12-12 | 2017-07-19 | Kalyra Pharmaceuticals, inc. | Bicyclic alkyl compounds and synthesis |
| CN113336653A (zh) * | 2014-03-07 | 2021-09-03 | 里科瑞尔姆Ip控股有限责任公司 | 螺桨烷衍生物及合成 |
| US10457502B2 (en) | 2014-05-22 | 2019-10-29 | Symbotic Canada Ulc | Tool and method for layer depalletizing |
| JP6833677B2 (ja) | 2014-09-17 | 2021-02-24 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | 二環式化合物 |
| US11058703B2 (en) * | 2015-12-31 | 2021-07-13 | Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. | Application of triacetyl-3-hydroxyphenyladenosine in preparation of pharmaceutical drug for preventing or treating non-alcoholic fatty liver disease |
| CN106580986B (zh) * | 2016-11-28 | 2017-09-15 | 王保亮 | 一种治疗少弱精子症的药物组合物 |
| BR112019024155A2 (pt) | 2017-05-15 | 2020-06-02 | Recurium Ip Holdings, Llc | Compostos analgésicos |
| IL274820B2 (en) * | 2017-11-21 | 2024-11-01 | Pfizer | Crystalline 2-amino-2-(hydroxymethyl)propane-1,3-diol salt of 4-(4-(1-isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4'-piperidine]-1'-carbonyl)-6-methoxypyridin-2-yl)benzoic acid |
| CN111574530B (zh) * | 2020-04-21 | 2022-07-26 | 徐州医科大学 | 一种acc抑制剂及其医药用途 |
| WO2024140923A1 (zh) * | 2022-12-30 | 2024-07-04 | 苏州浦合医药科技有限公司 | Prmt5-mta抑制剂 |
| WO2024213044A1 (en) * | 2023-04-14 | 2024-10-17 | Beijing Double-Crane Runchuang Technology Co., Ltd. | Azacyclo-carbonyl-fused ring derivatives and use thereof |
| WO2025036472A1 (en) * | 2023-08-16 | 2025-02-20 | Pharmaengine, Inc. | Spirocyclic mta-cooperative prmts inhibitor |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE364374T1 (de) | 1997-08-11 | 2007-07-15 | Pfizer Prod Inc | Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit |
| PL210793B1 (pl) | 2001-02-28 | 2012-03-30 | Merck & Co Inc | Acylowane pochodne piperydyny |
| EA200400980A1 (ru) | 2002-02-27 | 2005-02-24 | Пфайзер Продактс Инк. | Ингибиторы асс |
| US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
| JPWO2004092179A1 (ja) | 2003-04-14 | 2006-07-06 | 日本曹達株式会社 | スピロ誘導体、製造法および抗酸化薬 |
| JP2005119987A (ja) | 2003-10-15 | 2005-05-12 | Ajinomoto Co Inc | アシルスルホンアミド誘導体 |
| ES2327857T3 (es) | 2004-05-12 | 2009-11-04 | Pfizer Products Inc. | Derivados de prolina y su uso como inhibidores de la dipeptidil peptidasa iv. |
| US20050267221A1 (en) | 2004-05-14 | 2005-12-01 | Research Development Foundation | Use of curcumin and analogues thereof as inhibitors of ACC2 |
| WO2005116034A1 (en) | 2004-05-25 | 2005-12-08 | Pfizer Products Inc. | Tetraazabenzo[e]azulene derivatives and analogs thereof |
| PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
| ATE509023T1 (de) | 2005-07-19 | 2011-05-15 | Merck Sharp & Dohme | Spirochromanon-derivate als acetyl-koenzym-a- carboxylase-hemmer |
| WO2007013691A1 (ja) | 2005-07-29 | 2007-02-01 | Takeda Pharmaceutical Company Limited | スピロ環化合物 |
| DE602006019304D1 (de) | 2005-11-18 | 2011-02-10 | Merck Sharp & Dohme | Spirohydantoin-aryl-cgrp-rezeptorantagonisten |
| EP1991536A2 (en) | 2006-02-15 | 2008-11-19 | Abbott Laboratories | Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome |
| EP2010520B1 (en) | 2006-04-20 | 2012-09-12 | Pfizer Products Inc. | Heterobicyclic amides for the prevention and treatment of glucokinase-mediated diseases |
| CN101541809A (zh) | 2006-11-29 | 2009-09-23 | 辉瑞产品公司 | 螺环酮乙酰基-CoA羧化酶抑制剂 |
| PE20081559A1 (es) | 2007-01-12 | 2008-11-20 | Merck & Co Inc | DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA |
| JPWO2008102749A1 (ja) * | 2007-02-20 | 2010-05-27 | 武田薬品工業株式会社 | 複素環化合物 |
| JP5404601B2 (ja) | 2007-04-12 | 2014-02-05 | ファイザー・インク | 新規な３−アミド−ピロロ［３，４−ｃ］ピラゾール−５（１Ｈ，４Ｈ，６Ｈ）カルバルデヒド誘導体 |
| US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
| US7981904B2 (en) | 2008-03-20 | 2011-07-19 | Takeda Pharmaceutical Company Limited | Acetyl CoA carboxylase inhibitors |
| WO2009144554A1 (en) * | 2008-05-28 | 2009-12-03 | Pfizer, Inc. | Pyrazolospiroketone acetyl-c0a carboxylase inhibitors |
| CA2724603A1 (en) | 2008-05-28 | 2009-12-03 | Pfizer Inc. | Pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| WO2010002010A1 (en) * | 2008-07-04 | 2010-01-07 | Banyu Pharmaceutical Co.,Ltd. | Novel spirochromanone carboxylic acids |
| JP2011528034A (ja) | 2008-07-14 | 2011-11-10 | クロップソリューション，インコーポレイテッド | アセチル−補酵素カルボキシラーゼの修飾因子およびその使用方法 |
| US20110130365A1 (en) | 2008-07-29 | 2011-06-02 | Benbow John W | Fluorinated Heteroaryls |
| BRPI0918841B8 (pt) | 2008-08-28 | 2021-05-25 | Pfizer | derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol, seus cristais, composições farmacêuticas e usos |
| WO2010086820A1 (en) | 2009-02-02 | 2010-08-05 | Pfizer Inc. | 4-amino-5-oxo-7, 8-dihydropyrimido [5,4-f] [1,4] oxazepin-6 (5h) -yl) phenyl derivatives, pharmaceutical compositions and uses thereof |
| UA99882C2 (uk) | 2009-03-11 | 2012-10-10 | Пфайзер Інк. | Похідні бензофуранілу, фармацевтична композиція та спосіб лікування захворювань (варіанти) |
| WO2010103438A1 (en) | 2009-03-11 | 2010-09-16 | Pfizer Inc. | Substituted indazole amides and their use as glucokinase activators |
| JP2012520868A (ja) | 2009-03-20 | 2012-09-10 | ファイザー・インク | ３−オキサ−７−アザビシクロ［３．３．１］ノナン |
| US20120052130A1 (en) | 2009-05-08 | 2012-03-01 | Pfizer Inc. | Gpr 119 modulators |
| EP2427450A1 (en) | 2009-05-08 | 2012-03-14 | Pfizer Inc. | Gpr 119 modulators |
| PE20120399A1 (es) | 2009-06-05 | 2012-04-24 | Pfizer | Derivados del l-(piperidin-4-il)-pirazol como moduladores de gpr 119 |
| WO2011005611A1 (en) | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Neuromedin u receptor agonists and uses thereof |
| JP2013510191A (ja) * | 2009-11-10 | 2013-03-21 | ファイザー・インク | Ｎ−２ピラゾロスピロケトンアセチル−ＣｏＡカルボキシラーゼ阻害薬 |
| KR101478517B1 (ko) * | 2009-11-10 | 2015-01-02 | 화이자 인코포레이티드 | Ｎ1-피라졸로스피로케톤 아세틸-ｃｏａ 카복실라아제 억제제 |
| PL2621493T3 (pl) * | 2010-09-30 | 2017-01-31 | Pfizer Inc. | N1-pirazolospiroketonowe inhibitory karboksylazy acetylo-CoA |
-
2012
- 2012-04-09 HU HUE12718387A patent/HUE028602T2/hu unknown
- 2012-04-09 WO PCT/IB2012/051732 patent/WO2012143813A1/en active Application Filing
- 2012-04-09 SG SG2013075148A patent/SG194142A1/en unknown
- 2012-04-09 EP EP12718387.9A patent/EP2699576B1/en active Active
- 2012-04-09 PH PH1/2013/501941A patent/PH12013501941A1/en unknown
- 2012-04-09 PL PL12718387T patent/PL2699576T3/pl unknown
- 2012-04-09 PT PT127183879T patent/PT2699576E/pt unknown
- 2012-04-09 CN CN201280019621.3A patent/CN103492388A/zh active Pending
- 2012-04-09 MY MYPI2013003372A patent/MY162167A/en unknown
- 2012-04-09 AU AU2012245996A patent/AU2012245996B2/en not_active Ceased
- 2012-04-09 RS RS20160026A patent/RS54526B1/en unknown
- 2012-04-09 ES ES12718387.9T patent/ES2561452T3/es active Active
- 2012-04-09 MX MX2013012313A patent/MX348860B/es active IP Right Grant
- 2012-04-09 PE PE2013002387A patent/PE20141187A1/es not_active Application Discontinuation
- 2012-04-09 EA EA201391288A patent/EA022375B1/ru not_active IP Right Cessation
- 2012-04-09 SI SI201230417T patent/SI2699576T1/sl unknown
- 2012-04-09 MA MA36357A patent/MA35061B1/fr unknown
- 2012-04-09 KR KR1020137030875A patent/KR101567659B1/ko not_active Expired - Fee Related
- 2012-04-09 CA CA2831380A patent/CA2831380C/en active Active
- 2012-04-09 CU CU20130126A patent/CU24164B1/es active IP Right Grant
- 2012-04-09 NZ NZ616156A patent/NZ616156A/en not_active IP Right Cessation
- 2012-04-09 DK DK12718387.9T patent/DK2699576T3/en active
- 2012-04-09 GE GEAP201213267A patent/GEP20166474B/en unknown
- 2012-04-09 CN CN201610487378.8A patent/CN106117205B/zh not_active Expired - Fee Related
- 2012-04-09 JP JP2014505745A patent/JP5657174B2/ja active Active
- 2012-04-09 AP AP2013007129A patent/AP3499A/xx active
- 2012-04-09 ME MEP-2015-214A patent/ME02312B/me unknown
- 2012-04-18 TW TW101113766A patent/TWI464171B/zh not_active IP Right Cessation
- 2012-04-19 UY UY0001034027A patent/UY34027A/es not_active Application Discontinuation
- 2012-04-20 AR ARP120101364A patent/AR086198A1/es unknown
- 2012-04-21 US US13/452,839 patent/US8802688B2/en active Active
- 2012-09-04 UA UAA201311822A patent/UA107753C2/ru unknown
-
2013
- 2013-09-12 CR CR20130464A patent/CR20130464A/es unknown
- 2013-09-27 TN TNP2013000393A patent/TN2013000393A1/fr unknown
- 2013-09-27 CL CL2013002794A patent/CL2013002794A1/es unknown
- 2013-10-17 IL IL228949A patent/IL228949A/en active IP Right Grant
- 2013-10-18 GT GT201300258A patent/GT201300258A/es unknown
- 2013-10-18 NI NI201300111A patent/NI201300111A/es unknown
- 2013-10-21 DO DO2013000243A patent/DOP2013000243A/es unknown
- 2013-10-24 CO CO13252716A patent/CO6801757A2/es active IP Right Grant
- 2013-11-22 EC ECSP13013038 patent/ECSP13013038A/es unknown
-
2014
- 2014-07-08 US US14/325,420 patent/US20140323730A1/en not_active Abandoned
-
2015
- 2015-01-09 US US14/593,370 patent/US20150112068A1/en not_active Abandoned
- 2015-08-07 US US14/820,884 patent/US20150336958A1/en not_active Abandoned
- 2015-12-21 HR HRP20151397TT patent/HRP20151397T1/hr unknown
-
2016
- 2016-01-14 CY CY20161100038T patent/CY1117122T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP13013038A (es) | Inhibidores sustituidos de acetil-coa carboxilasa | |
| UY33694A (es) | ?inhibidores de n1/n2-lactama acetil-coa carboxilasa?. | |
| CR20120190A (es) | INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA | |
| DOP2019000010A (es) | Compuesto (r)-n-(5-cloro-1-(3,3-difluoro-1-(oxetan-3-il)piperidin-4-il)-1h-pirazol-4-il)-4-etoxi-7h-pirrolo[2,3-d]pirimidin-2-amina o sal farmacéuticamente aceptable del mismo | |
| MX2015012822A (es) | 3-pirimidin-4-il-oxazolidin-2-onas- como inhibidores del idh mutante. | |
| PH12015502018A1 (en) | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh | |
| TN2014000128A1 (en) | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh | |
| PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| DOP2014000152A (es) | Inhibidores de bromodominios | |
| EA201691803A1 (ru) | Ингибиторы калликреина плазмы человека | |
| UY35395A (es) | Inhibidores de bromodominios tetracíclicos | |
| MD4666B1 (ro) | Inhibitori ai Syk | |
| PE20121617A1 (es) | Derivados de oxazina como inhibidores de bace | |
| MY167898A (en) | Co-crystals and salts of ccr3-inhibitors | |
| MX390051B (es) | Antagonistas de ep4. | |
| EA201400067A1 (ru) | Новая терапевтическая композиция, содержащая апоморфин в качестве активного ингредиента | |
| PE20142450A1 (es) | Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1 | |
| TN2013000150A1 (en) | Co-crystals and salts of ccr3-inhibitors | |
| NZ621471A (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |